Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

As the U.S. continues to wait for newer sunscreen ingredients, patients should use tinted sunscreens to protect against visible light that causes photodamage, melasma and hyperpigmentation, according ...

Q4 2024 Earnings Call Transcript February 6, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

Christopher Boerner; Chairman of the Board, Chief Executive Officer, Chief Operating Officer; Bristol-Myers Squibb Co David Elkins; Executive Vice President, Chief Financial Officer, Member of the ...

The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.

The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...

Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this ...

Just nine months after announcing a massive plan to cut costs, Bristol Myers Squibb has gone one better, revealing a new goal to save even more money.

Revenue: Q4 of $3.33 billion vs $3.03 billion; Full year of $13.01 billion vs $12.16 billionDiluted EPS: Q4 of $1.70 vs $(1.95); Full year of $8.84 vs ...